InnoPharma China Congress 2011

Why You Can’t Miss InnoPharma China Congress 2011

• To know first in time new GMP and drug distribution development program

• Best practices to learn from in the globe

• Better cooperate with SFDA to make drug launch easier

• Approach of efficiency R & D, R & D outsourcing

• Find the most suitable CRO partner in China

• Learn the operation strategies to maximize the productivity of clinical trials

• Face-to-face biz talks & networking

The Background of InnoPharma China Congress 2011

Last year, the world economy did not melt down. Pharma industry has not seen the widespread bloodletting that many were expecting. Things are different and they are more difficult, but many of the current challenges can also be viewed as intensified versions of opportunities that pharma industry has witnessed in terms of industrial structure transformation. For this industry, dealing with challenges is the only normal it has ever known. The pharma industry’s resilience has always been based on innovation — in science and in business modes.

It is evident that China will be an increasingly important market for pharmaceutical products and companies in the years to come. The Chinese market is a market currently dominated by generics and traditional Chinese medicines (TCMs). Meanwhile, the Chinese Government is encouraging the development of a domestic innovative biotechnology sector through a combination of direct investment, intellectual property reforms and commercial incentives.

InnoPharma China Congress 2011 of JFPS Group will invite more than 200 InnoPharma leaders and pioneers to bring you the latest trends in the industry which are highly interesting. It is a grand platform for face-to-face communication with drug discovery, clinical and regulatory issues in the industry.